PERBIOIMAGE
Exploring pericyclic reactions for bioorthogonal imaging of biological processes with molecular precision
| Coordinatore | INSTITUTO DE MEDICINA MOLECULAR
Organization address
address: AVENIDA PROF EGAS MONIZ contact info |
| Nazionalità Coordinatore | Portugal [PT] |
| Totale costo | 100˙000 € |
| EC contributo | 100˙000 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2013-CIG |
| Funding Scheme | MC-CIG |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-04-01 - 2018-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTITUTO DE MEDICINA MOLECULAR
Organization address
address: AVENIDA PROF EGAS MONIZ contact info |
PT (LISBOA) | coordinator | 100˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Bioorthogonal reactions have become essential tools for Chemical Biology and Drug Discovery. Despite recent advances in the development of bioorthogonal reactions, there still exists a need for reactions with improved kinetics and selectivities. Alkenes have been exploited in the context of site-specific protein modification and labelling, for example in cross-metathesis, photochemical 1,3-dipolar cycloaddition and tetrazine Diels-Alder cycloaddition strategies. Pericyclic reactions are a class of reactions where alkenes are suitable partners to achieve selectivity. These reactions are particularly attractive for applications in biological systems because their often-accelerated rate in polar media and their concerted mechanisms reduce undesired reactivity with biological nucleophiles and electrophiles. This project aims to 1) explore the reactivity of alkenes in benign aqueous conditions for site-specific ligand/protein labelling using a photoinduced [22] cycloaddition strategy, 2) site-specific incorporation of bioorthogonal group norbornadiene via genetic code expansion for directed site-specific cellular protein labeling, 3) the design and synthesis of ligands of ligands of oncogenic IL7R in T-cell acute lymphoblastic leukaemia (T-ALL) and 4) the use of a bioorthogonal approach for live cell imaging of oncogenic IL7R in T-ALL.'